Showing results (91-100 of 212) with videos related to
Sort By:
Pageof 22
Breast Cancer Research and Treatment|April 25, 2012
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxelDaniel L Hertz, Alison A Motsinger-Reif, Amy Drobish, et al.Pharmacogenetics|August 2, 2003
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samplesJames M Rae, Kevin E Cordero, Joshua O Scheys, et al.The Journal of Pharmacology and Experimental Therapeutics|May 13, 2006
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cellsYoung Chai Lim, Lang Li, Zeruesenay Desta, et al.Breast Cancer Research and Treatment|September 21, 2004
EGFR and EGFRvIII expression in primary breast cancer and cell linesJames M Rae, Joshua O Scheys, Kim M Clark, et al.Breast Cancer Research and Treatment|June 30, 2005
GREB 1 is a critical regulator of hormone dependent breast cancer growthJames M Rae, Michael D Johnson, Joshua O Scheys, et al.Breast Cancer Research and Treatment|June 4, 2008
The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistanceMatthew J Sikora, Kevin E Cordero, Jose M Larios, et al.Journal of Medical Internet Research|February 5, 2025
Remote Monitoring of Chemotherapy-Induced Peripheral Neuropathy by the NeuroDetect iOS App: Observational Cohort Study of Patients With CancerCiao-Sin Chen, Michael P Dorsch, Sarah Alsomairy, et al.British Journal of Clinical Pharmacology|June 12, 2012
Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposureDaniel L Hertz, Christine M Walko, Arlene S Bridges, et al.Hormones & Cancer|October 8, 2011
Functional characterization of a genetic polymorphism in the promoter of the ESR2 geneSantosh Philips, Alexandra Richter, Steffi Oesterreich, et al.Pharmacogenomics|January 7, 2021
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapyFaisal Shakeel, Fang Fang, Jung Won Kwon, et al.Pageof 22